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The onset of Leber hereditary optic neuropathy is relatively rare in childhood and,
interestingly, the rate of spontaneous visual recovery is very high in this group of patients.
Here, we report a child harboring a rare pathological mitochondrial DNA mutation,
present in heteroplasmy, associated with the disease. A patient follow-up showed a rapid
recovery of the vision accompanied by a decrease of the percentage of mutated mtDNA.
A retrospective study on the age of recovery of all childhood-onset Leber hereditary optic
neuropathy patients reported in the literature suggested that this process was probably
related with pubertal changes.
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INTRODUCTION
Leber hereditary optic neuropathy (LHON) is a type of blindness, usually characterized by severe
central vision loss in one eye soon followed by the fellow eye, associated dense scotomas and
impaired color vision. Ninety percent of the patients with this disease have been associated with
one of the following point mutations within the mitochondrial DNA (mtDNA): m.3460G>A,
m.11778G>A, and m.14484T>C. A plethora of rare mutations is responsible for the remaining
10% and some of them have been previously associated to other mitochondrial phenotypes.
LHONmainly affects young adult men. The peak age of onset is in the second and third decades
of life (Majander et al., 2017). The onset of the disease in childhood is relatively rare. Thus, it has
been reported that<10% of patients were 12 year-old or younger at the time of diagnosis (Majander
et al., 2017). Notably, in this patient population, the rate of spontaneous visual recovery is very high
(Majander et al., 2017). However, the reason for such spontaneous recovery is unknown and there
is hardly any information on either biochemical nor lifestyle of the patients around the recovery
period.
Hereby in the present paper, we report a case of a child suffering LHON who presents a rare
mtDNA mutation. Biochemical, cellular and genetic studies performed on patient’ fibroblasts and
cybrids show that this mutation is pathological. Interestingly enough, the patient rapidly recovered
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his vision. We also discuss a potential correlation of the age
of recovery of childhood-onset LHON patients with pubertal
changes since two thirds of these patients recovered sight before
the age of 13.
MATERIALS AND METHODS
Case Report
A 10 year-old male came to our department referring bilateral
and painless visual loss. Upon examination, visual acuity (VA)
was 20/400 (1.3 logarithm of the minimum angle resolution-
LogMAR) right eye (RE) and 20/100 (0.7 LogMAR) left
eye (LE), Ishihara Test: 0/20 RE and 5/20 LE. Pupils were
slightly anisocoric (RE > LE), with normal responses to light.
Anterior segment was normal in both eyes, and ocular fundus
showed temporal optic disc pallor RE and a congestive disc
with telangiectasies LE (Figure 1A). Brain magnetic resonance
was performed with normal results. The electroretinogram
study was normal and visual evoked potential study showed
a bilateral delay of conduction through the visual pathways
suggestive of bilateral optic neuropathy (Figures 1B,C). After
6 months the RE showed a favorable evolution, with VA of
20/25 (0.1 LogMAR) but VA in the LE stayed at 20/100
(0.7 LogMAR). Ishihara test was 18/20 in RE and 1/20 in
LE, and a slight relative afferent pupillary defect was observed
in the LE. The visual fields showed a paracentral scotoma
in the RE and a cecocentral scotoma in the LE. Fundoscopy
revealed bilateral marked optic disc pallor (LE > RE) with
an associate vascular attenuation (Figure 1D). There was a
stabilization of the clinical picture over the following 2 years.
Ultimately, the patient has experienced a favorable evolution
after 4 years from the beginning of the clinical symptoms. His
VA has presently improved to 20/20 RE (0.0 LogMAR) and
20/40 LE (0.3 LogMAR) with an improvement of the Ishihara
test to 20/20 RE and 20/20 LE. Visual fields show minimal
defects in the RE and a 5 degree central scotoma in the LE.
However, bilateral pallor of the optic discs remains in the ocular
fundus (Figures 1E,F). This study was approved by and carried
out in accordance to the recommendations of Institutional
Review Board from the Government of Aragón (CEICA CP-
12/2014). The patient’s mother written informed consent was
obtained for their participation in the study, in accordance with
the Declaration of Helsinki, and for publication of the case
report.
Molecular-Genetic Analyses
Total DNA was extracted by standard methods. Screening
for the three primary LHON mutations was performed by
polymerase chain reaction (PCR)/restriction fragment length
polymorphism (RFLP) (Supplementary Table 1). The complete
mtDNA was amplified and sequenced according to previously
described protocols (Supplementary Table 2; Gomez-Duran
et al., 2010). The percentage of m.13094T>C transition was
analyzed by PCR/RFLP by using protocols described elsewhere
(Valente et al., 2009). The mtDNA content was measured,
in triplicate in three independent experiments, by the real-
time quantitative reverse transcription-PCR (RT-qPCR) method
using an Applied Biosystems StepOneTM Real-Time PCR System
Thermal Cycling Block, as described elsewhere (Andreu et al.,
2009).
Production of Transmitochondrial Cell
Lines and Cell Culture
To homogenize nuclear and environmental factors, we produced
transmitochondrial cell lines (cytoplasmic hybrids or cybrids)
with the osteosarcoma 143B rho0 nuclear background using
patient and control platelets (Chomyn, 1996). These cybrids, as
well as patient and control fibroblasts, were grown in Dulbecco’s
modified eagle medium with no antibiotics and containing
glucose (4.5 g/l), pyruvate (0.11 g/l) and 5 or 10% of fetal bovine
serum (FBS), respectively.
Biochemical Investigations
The analyses of oxygen consumption, ATP, mitochondrial inner
membrane potential (MIMP) and H2O2 levels were performed in
triplicate in 3 independent experiments according to previously
described protocols (Gomez-Duran et al., 2010; Llobet et al.,
2015). The activity of several mitochondrial complexes was
analyzed using BN-PAGE in-gel activity technique (Wittig
et al., 2007). Western blots in cellular lysates were performed
using Total OXPHOS Human WB Antibody Cocktail (1:1,000,
ab110411, ABCAM), anti-LC3B (1:1,000, L7543, Sigma) and anti-
actin (1:2,000, A2066, Sigma) as primary antibodies (Lopez-
Gallardo et al., 2009).
Molecular Modeling
The three-dimensional structure of the bovine p.MT-ND5 (PDB
5LNK) was obtained with the RasMol 2.6 program (http://www.
rasmol.org).
Statistical Analysis
The statistical package StatView 6.0 was used to perform
all the statistics. Data for mean and standard deviation are
presented. The unpaired two-tailed t-test was used to compare
parameters. P-values lower than 0.05 were considered statistically
significant.
RESULTS
The three most common LHON mutations (m.3460G>A,
m.11778G>A, and m.14484T>C) are responsible for
approximately 90% of all LHON cases (Majander et al.,
2017). Therefore, we tested their presence by PCR-RFLP
and ruled them out. Next, we sequenced the whole mtDNA
from blood cells and assigned it to mitochondrial haplogroup
H1 (Van Oven and Kayser, 2009). This mtDNA harbored
4 private mutations (GenBank MG386502): m.11113T>C
synonymous and homoplasmic mutation in the MT-ND4
gene; m.13094T>C in the MT-ND5 gene; m.15527C>T in
the MT-CYB gene; and the highly frequent and homoplasmic
m.16295C>T mutation in the MT-CR control region. One of
the two non-synonymous variants, the m.15527C>T transition,
is a homoplasmic mutation (Supplementary Figure 1A)
which has not been reported in 37,545 published human
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FIGURE 1 | Ocular exam. (A) Fundus photography. RE shows temporal optic disc pallor. LE shows a congestive disc with telangiectasies. (B) Electroretinogram.
(C) Visual evoked potential pattern. Bilateral delay of conduction through the visual pathways is observed. (D) Fundus photography. Bilateral pallor of the optic discs
remains. (E,F) Visual fields analysis. RE and LE show a paracentral and a cecocentral scotoma, respectively.
mtDNA sequences (GenBank, November 3, 2017), although
it was present in homoplasmy in mother’s blood and urine
(Supplementary Figure 1B). This mutation causes a proline to
serine substitution in p.MT-CYB position 261. This proline
is conserved in 94.7% of 4,988 eukaryotic (from protists to
mammals) p.MT-CYB sequences (Martin-Navarro et al., 2017).
Pathogenicity predictors, such as MutPred (Pereira et al., 2011),
PolyPhen-2 and Mitoclass.1 (Martin-Navarro et al., 2017),
consider this amino acid substitution as a pathogenic mutation.
The m.13094T>C mutation has not been reported in these
37,545 human sequences. This is a heteroplasmic mutation
(Figure 2A) and its percentage varies between patient tissues
(Figures 2B,C). Said mutation was not found in blood or urine
of his younger brother nor in his mother’s blood but it was
present, in a low percentage (10%), in the urine of his mother
(Figure 2B). This m.13094T>C transition provokes a valine to
alanine change in p.MT-ND5 position 253 (Figure 2D). The
valine is conserved in 99.7% of 5,159 eukaryotic p.MT-ND5
sequences (Martin-Navarro et al., 2017). This Val253 is located
in the p.MT-ND5 transmembrane helix 8 (TMH8), following
a serine pair (Ser249 and Ser250) that distorts TMH8 (Zhu
et al., 2016), and a key His248 sit on a flexible loop of the
discontinuous TMH8. This mid-membrane break/loop lend
flexibility to key protonable residues (Fiedorczuk et al., 2016;
Figure 2D). PolyPhen-2 and Mitoclass.1 consider this amino
acid substitution as a pathogenic one, but as for MutPred its
pathogenicity is low.
Along 3 years, four different blood analysis were performed
and the percentage of m.13094T>C mutation decreased
from 50% to undetectable (Figure 2E), but the m.15527C>T
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FIGURE 2 | mtDNA m.13094T>C mutation. (A) Electropherogram showing the presence of the heteroplasmic mutation in the patient. (B,C) Mutation load in different
members of the family. (D) Molecular model of p.MT-ND5 subunit. Respiratory complex I (CI), p.MT-ND5 polypeptide and transmembrane helix 8 (TMH8) showing the
affected amino acid. (E,F) Mutation load variation through time in patient’s blood. M, DNA molecular weight marker VIII (Roche); A, amplicon; C-, negative control; P,
patient; Br, brother; Mo, mother; B, U, F, patient blood, urine and fibroblasts; PB, 1-5, patient blood indicating the dates. Uncropped images for gels in B,C can be
found in Supplementary Figure 2A,B, respectively.
transition stayed homoplasmic (Supplementary Figure 1C).
Simultaneously, there was an improvement in visual acuities
to an eventually almost complete visual recovery. However,
another blood sample, 8 months later, showed a 15–20% of
the m.13094T>C mutation (Figure 2F), although the vision
was not altered. mtDNA copy numbers in blood from different
ages [Patient Blood 2 (PB2), 78.8 copies/cell ± 4.71 (2); PB3,
35.0 copies/cell ± 0.22 (2); PB4, 55.5 copies/cell ± 2.75 (2);
PB5, 69.3 copies/cell ± 0.30 (2)] were not correlated with the
percentage of mutation. As LHON affected cells are the retinal
ganglion cells (RGCs), this visual recovery with reduction in
blood mutation load was probably accompanied by a decline in
the RGCs mutation load. The onset of LHON is relatively rare
in childhood, but their prognosis is more favorable (Majander
et al., 2017). Thus, from 14 childhood-onset LHON patients (age
of onset, 2–12 years) who showed visual recovery (exactly dated),
10 have got it before the age of 13 (Mackey and Howell, 1992;
Kawasaki and Borruat, 2005; Sharkawi et al., 2012; Majander
et al., 2017).
Next, we checked cellular effects of these mtDNA mutations
in the patient’s fibroblasts. Basal and uncoupled respiration
and ATP levels were significantly decreased in patient’s vs.
control’s fibroblasts (Figures 3A,B). There was no difference
in the levels of hydrogen peroxide (Figure 3B). On the
other hand, mitochondrial inner membrane potential was
significantly increased in patient’s fibroblasts (Figure 3B). An
in gel activity analysis showed an important decrease in
complex I (CI) and V (CV) activities (Figure 3C). The mtDNA
amount was also significantly lower in the patient’s fibroblasts
(Figure 3D).
In the patient’s vs control’s fibroblasts comparison, culture
conditions are homogenized, but nuclear DNA (nDNA) and
mtDNA genetic backgrounds differ. On the contrary, in cybrids
the nDNA is also homogeneous and they only differ in
the mtDNA genotype. Therefore, we used osteosarcoma 143B
rho0 cells to build mutant and control cybrids (Figure 4A
and Supplementary Figure 1D). The short terminal repeats
(STR) markers reported in the American Type Culture
Collection (ATCC) for the osteosarcoma 143B cell line did
not differ from those of the cell lines used in this work,
and they are the same than those previously reported in
other osteosarcoma 143B cybrids (Lopez-Gallardo et al., 2014),
thus confirming the nDNA homogeneity. Basal and uncoupled
oxygen consumptions were significantly lower in mutant cells
(Figure 4B), and this was accompanied by lesser cell ATP
amount. The ATP levels were higher in cybrids with lower
percentages of m.13094T>C mutation, although they were
homoplasmic for the m.15527C>T transition (Figure 4C and
Supplementary Figure 1D). Surprisingly, we found an inverse
relationship between the percentage of m.13094T>C mutation
and the mtDNA copy numbers [0%, 950 copies/cell ± 1 (1);
20%, 737 copies/cell ± 159 (8); 50%, 541 copies/cell ± 41
(3)]. Although levels of nDNA (CI-20kDa, CII-30kDa, CIII-
Core2, and CV-F1a) and mtDNA (CIV-p.MT-CO2) subunits
did not differ (Figure 4D), the in gel activity analysis showed
an important decrease in CI and CIV activities, and CV
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FIGURE 3 | Mitochondrial biochemical characterization of the patient’s fibroblasts. (A) Oxygen consumption. (B) ATP and reactive oxygen species (ROS) levels and
mitochondrial inner membrane potential (MIMP). (C) In gel complexes activity. (D) mtDNA quantity. CF, PF, CI, CII, CIV, CV, and Rho0 code for control fibroblasts,
patient fibroblasts, complex I, complex II, complex IV, complex V, and cells without mtDNA, respectively. Dashed line represents the control fibroblast values. *, **, ***
indicate < 0.05, 0.01, and 0.001 p-values, respectively.
sub-complexes were also observed (Figure 4E). Autophagy,
determined as LC3B-II/Actin levels, was significantly increased
in mutant cybrids (Figure 4F).
DISCUSSION
We found two potential mtDNA pathologic mutations in the
patient. The change in ATP levels of mutant cybrids, despite
all of them harboring a homoplasmic m.15527C>T transition,
along with other considerations make us rule out this mutation
as the pathologic one for this patient. However, the m.13094T>C
heteroplasmic mutation had been previously associated to two
other patients. The first was a 7 year-old child suffering from
Ataxia and Progressive External Ophthalmoplegia (PEO). The
skeletal muscle biopsy was morphologically normal. Muscle and
fibroblast were also biochemically normal. However, mutant
fibroblasts had a clear reduction in CI in gel activity and CI-
sub-complexes in a 2D-BNGE WB analysis. In osteosarcoma
143B cybrids, the CI/CS ratio negatively correlated with the
percentage of mutation and the 80% mutant cybrid showed CI
sub-complexes. Mutant and control CI amount was comparable
in fibroblasts and also in cybrids (Valente et al., 2009). This
heteroplasmic mutation was also found in a 34 year-old woman
with Kearns-Sayre syndrome (Lax et al., 2012a although, in
Lax et al., 2012b, this patient is referred as suffering from
mitochondrial encephalomyopathy with lactic acidosis and
stroke-like episodes (MELAS)/Leigh syndrome (LS), myoclonus
and fatigue). A vascular smooth muscle cell loss was observed
along with thinning of the vascular smooth muscle cell layer
and 50% of neurons were lost from the olivo-cerebelum (Lax
et al., 2012a,b). On the other hand, besides m.13094T>C, several
p.MT-ND5 mutations have been also associated with LHON
or LHON-like phenotypes, and some of them were previously
associated to other phenotypes, such as MELAS or LS (www.
mitomap.org). Our evidences, along with those from these two
other articles, strongly support the m.13094T>C transition as
a pathologic mutation for PEO, MELAS/LS (KSS), or LHON.
Probably, tissue distribution and percentage of the mutation
are responsible for these different phenotypes. Interestingly, this
mutation seemed to trigger a decrease in mtDNA amount that
could be responsible for the OXPHOS multienzymatic deficit in
patient fibroblasts and cybrids.
The decrease in mutation levels is probably responsible for
the patient’s recovery. A reduction in the mutation load in
proliferative tissues has been observed in some longitudinal
studies for LHON mutations (Howell et al., 2000; Jacobi et al.,
2001; Puomila et al., 2002; Kaplanova et al., 2004). However,
the decrease is mostly moderate. Only 2 patients and 2 carriers
harboring the m.3460G>A LHONmutation showed a reduction
≥10% (Supplementary Table 3). One of the patients, who
recovered the vision, showed a reduction in the mutation load
from 46 to 35% over the following 5 years. Our patient, who also
recovered vision, showed a 50% decrease in the blood mutation
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FIGURE 4 | Biochemical characterization of the normal and 50% mutation cybrid cell lines. (A) Gel showing the percentage of the m.13094T>C mutation. (B) oxygen
consumption. (C) ATP levels in cybrids harboring different (0, 20, and 50%) m.13094T>C mutation load. (D) Levels of different OXPHOS subunits (in brackets) in
cellular lysates. (E) In gel complexes activity. White asterisks denote CV subcomplexes. (F) Western blot quantification of the LC3BII autophagy marker, normalized to
actin, in cellular lysates. M, DNA molecular weight marker VIII (Roche); CC and PC denote control and patient (50% mutation) cybrids, respectively. CI, CII, CIII, CIV,
and CV code for complex I, complex II, complex III, complex IV and complex V, respectively. Dashed line represents the control cybrid values. *, *** indicate < 0.05
and 0.001 p-values, respectively. Uncropped image for gel in (A) can be found in Supplementary Figure 2C. Results for (F) can be found in Supplementary Figure 2D.
load. Blood is not the affected tissue in LHON patients, but RGCs
is. These cells are mostly inaccessible for genetic tests. Then, why
should the blood mutation load be related to the visual health?
Despite tissue-specific directional selection for different mtDNA
genotypes has been reported (Jenuth et al., 1997), it was also
observed that a high amount of mutated mtDNA in leukocytes
was also correlated to a high proportion in other tissues (Juvonen
et al., 1997).
We have not been able to note any particular changes in the
patient’s life style as a potential cause of this decrease in the
mutation load and vision recovery. We had previously found
higher mtDNA content in peripheral blood cells of unaffected
heteroplasmic mutation carriers with respect to the affected
ones (Bianco et al., 2017). Moreover, many patients showing
visual recovery are homoplasmic individuals. In these cases,
their improvement cannot be associated to a reduction in the
mutation load. Visual recovery of these individuals may also
be accompanied by an increase in their RGCs mtDNA levels
mirrored in their blood mtDNA levels. In fact, mtDNA content
in peripheral blood cells is higher in unaffected homoplasmic
mutation carriers with respect to the affected ones (Bianco
et al., 2016). Remarkably, more than two thirds of unaffected
homoplasmic carriers are female (Bianco et al., 2016), and it has
been observed that oestradiol increases mtDNA content, which it
could explain the lower LHON prevalence in females (Giordano
et al., 2011). LHON is also less prevalent in prepubertal girls
(Majander et al., 2017). Interestingly, oestradiol values are higher
in prepubertal girls than in prepubertal boys and these levels
increase with age and pubertal stage in both sexes (Ikegami
et al., 2001; Janfaza et al., 2006). This rise in prepubertal
oestradiol levels could be responsible for the high spontaneous
visual recovery rate of childhood LHON patients (Majander
et al., 2017). In this case, prepubertal oestradiol concentration
might be a biomarker for childhood LHON. More importantly,
transiently increasing oestradiol concentrations perhaps avoided
the blindness or accelerated the recovery.
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